Expression and function of efflux drug transporters in the intestine.
about
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia TherapyAge-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilersQuantitative Assessment of the Influence of Rhizoma Zingiberis on the Level of Aconitine in Rat Gut Sacs and Qualitative Analysis of the Major Influencing Components of Rhizoma Zingiberis on Aconitine Using UPLC/MSA comparative evaluation of models to predict human intestinal metabolism from nonclinical data.New inhibitors of ABCG2 identified by high-throughput screeningMRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.Tea catechin auto-oxidation dimers are accumulated and retained by Caco-2 human intestinal cellsDefining the Human Brain Proteome Using Transcriptomics and Antibody-Based Profiling with a Focus on the Cerebral Cortex.Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Multigene predictors of tacrolimus exposure in kidney transplant recipients.How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.Characteristic Analysis of Intestinal Transport in Enterocyte-Like Cells Differentiated from Human Induced Pluripotent Stem Cells.Inhibition of OCTN2-mediated transport of carnitine by etoposide.Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy.Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in MicePharmacogenetics of opioids.HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug DispositionNew fluphenazine analogues as inhibitors of P-glycoprotein in human lymphocyte culturesTransporter-mediated uptake into cellular compartments.Involvement of P-glycoprotein and multidrug resistance associated protein 1 on the transepithelial transport of a mercaptoacetamide-based histone-deacetylase inhibitor in Caco-2 cells.Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipientsInterindividual variability of methadone response: impact of genetic polymorphism.Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.Abcb1 in Pigs: Molecular cloning, tissues distribution, functional analysis, and its effect on pharmacokinetics of enrofloxacin.Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis.ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs.Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues.Cytochrome P450 and P-Glycoprotein-Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases.ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.ABCB1 and ABCG2 expression in the placenta and fetus: an interspecies comparison.Biomagnetic methods: technologies applied to pharmaceutical research.Herb-drug pharmacokinetic interactions reviewed.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.The role of sphingolipids in drug metabolism and transport.Polyamines and membrane transporters.Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications.Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells.
P2860
Q26780502-69D4663F-47A8-439E-9866-879848092899Q28533470-2AF8F26A-B90F-478E-A895-8B6EE1290E1CQ28547282-7963EB09-6EC7-4088-AA6D-A294D895D3C9Q31159063-93C3CCAA-990B-4269-A3AB-B9F07FA5198FQ33311099-D4D128C1-BF66-4C27-BCBB-F672799152D2Q33554403-80AD4E8D-2A8C-47AC-A25E-E80F7C6256C9Q34069298-DE06CC7F-E7F3-4E9D-9F3E-1E61051D32A0Q34089821-73B6E0E6-0B73-4FF4-A82F-1D11D63CD168Q35664307-13A45E9D-7429-4B90-A88D-7C5683579E76Q35814091-AFF9C7CA-1442-4BB5-8D73-73DA76387A92Q35924246-AA358CD5-C02D-4356-9E35-26A48FA236B1Q36028281-EE50B7A9-638A-4417-A5E0-FB295108B9EEQ36078060-C56CCAAB-625A-4226-BF07-B959AFBBCE50Q36302949-EA381240-5187-4568-9EDA-43088AF3D6E4Q36403439-F1EFA923-8245-499F-A235-B701E36B2927Q36618672-CF25CF51-7720-4617-83BE-938B40283131Q36752672-9281F898-5EAF-42C2-9137-5DB5698AAB9FQ36888037-FF7CC40B-7AFD-47D8-BDE4-05FA0F09F5B4Q36942582-D6E1666A-5A55-4FB8-901E-417727C50E27Q36985076-88E4876B-80FE-4855-A705-8B44A8A2A5CFQ37011590-E25588F5-E209-4EF3-B07C-2252463766D8Q37126092-A2212130-9CCC-424A-8BC1-08A0A723D1FEQ37142009-D90E138A-C343-4C1B-9FDE-28A7EB0242BEQ37148784-E26FF9F6-CED6-484E-BEF1-9E058685D925Q37215781-12F39E43-808D-4C88-A676-381785257BCBQ37556541-E4825178-0CE6-4206-881B-46B1D110E617Q37575649-86AAECB5-90CF-4A7B-9891-F03139826E9BQ37604379-2BFC651D-A636-4C47-A11F-B1CC4F771B57Q37640084-7920D25C-DD19-4C89-9B88-E072E170B127Q37724178-EEC98A08-B184-4D27-9433-CB48CC08608CQ37782354-B45EC688-6BE4-495E-A44A-D3E1F527C420Q37800414-8BBA53C4-CD2C-4509-9F11-BF51219A92FEQ37808478-38CDB20F-E2E9-4FEB-A82C-96FED308C848Q38003174-CB8536A3-E4A0-4614-A6D5-6DD3D458D836Q38071694-84A575C6-F25A-40AE-A7A3-79C23CB413F8Q38121425-442502E3-C849-4316-8224-8AF74AB773FCQ38245668-6ABF5EE5-94FC-41B4-A9EB-D27FF293C5D6Q38262203-D9D8EFAC-2929-4B7E-A0CF-E59438310773Q38267703-1B3643DB-1F3C-4765-9BE6-27C11142FB87Q38286395-E27E01CF-908A-4395-8F23-396D21CC2187
P2860
Expression and function of efflux drug transporters in the intestine.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Expression and function of efflux drug transporters in the intestine.
@ast
Expression and function of efflux drug transporters in the intestine.
@en
type
label
Expression and function of efflux drug transporters in the intestine.
@ast
Expression and function of efflux drug transporters in the intestine.
@en
prefLabel
Expression and function of efflux drug transporters in the intestine.
@ast
Expression and function of efflux drug transporters in the intestine.
@en
P2093
P1476
Expression and function of efflux drug transporters in the intestine.
@en
P2093
Mikihisa Takano
Ryoko Yumoto
Teruo Murakami
P304
P356
10.1016/J.PHARMTHERA.2005.06.005
P577
2005-10-04T00:00:00Z